- Home
- HLP vs CNTB Comparison
HLP vs CNTB Comparison
Compare HLP & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- CNTB
- Stock Information
- Founded
- HLP 2021
- CNTB 2012
- Country
- HLP China
- CNTB United States
- Employees
- HLP N/A
- CNTB N/A
- Industry
- HLP Industrial Machinery/Components
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- HLP Industrials
- CNTB Health Care
- Exchange
- HLP Nasdaq
- CNTB Nasdaq
- Market Cap
- HLP 52.1M
- CNTB 54.4M
- IPO Year
- HLP 2023
- CNTB 2021
- Fundamental
- Price
- HLP $0.69
- CNTB $1.81
- Analyst Decision
- HLP
- CNTB Strong Buy
- Analyst Count
- HLP 0
- CNTB 2
- Target Price
- HLP N/A
- CNTB $7.50
- AVG Volume (30 Days)
- HLP 207.2K
- CNTB 131.0K
- Earning Date
- HLP 09-18-2025
- CNTB 08-13-2025
- Dividend Yield
- HLP N/A
- CNTB N/A
- EPS Growth
- HLP N/A
- CNTB N/A
- EPS
- HLP N/A
- CNTB N/A
- Revenue
- HLP $14,105,620.00
- CNTB $1,965,000.00
- Revenue This Year
- HLP N/A
- CNTB N/A
- Revenue Next Year
- HLP N/A
- CNTB N/A
- P/E Ratio
- HLP N/A
- CNTB N/A
- Revenue Growth
- HLP N/A
- CNTB N/A
- 52 Week Low
- HLP $0.61
- CNTB $0.51
- 52 Week High
- HLP $2.13
- CNTB $2.86
- Technical
- Relative Strength Index (RSI)
- HLP 48.54
- CNTB 48.52
- Support Level
- HLP $0.66
- CNTB $1.70
- Resistance Level
- HLP $0.68
- CNTB $1.92
- Average True Range (ATR)
- HLP 0.05
- CNTB 0.21
- MACD
- HLP 0.01
- CNTB -0.05
- Stochastic Oscillator
- HLP 40.08
- CNTB 25.56
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.